High-altitude cerebral edema

Last updated
High-altitude cerebral edema
Other namesHigh-altitude cerebral oedema [1] (HACO)

High-altitude cerebral edema (HACE) is a medical condition in which the brain swells with fluid because of the physiological effects of traveling to a high altitude. It generally appears in patients who have acute mountain sickness and involves disorientation, lethargy, and nausea among other symptoms. It occurs when the body fails to acclimatize while ascending to a high altitude.

Contents

It appears to be a vasogenic edema (fluid penetration of the blood–brain barrier), although cytotoxic edema (cellular retention of fluids) may play a role as well. Individuals with the condition must immediately descend to a lower altitude or coma and death can occur. Patients are usually given supplemental oxygen and dexamethasone as well.

HACE can be prevented by ascending to heights slowly to allow the body more time to acclimatize. Acetazolamide also helps prevent the condition. Untreated patients usually die within 48 hours. Those who receive treatment may take weeks to fully recover. It is a rare condition, occurring in less than one percent of people who ascend to 4,000 metres (13,000 ft). Although it was first described in 1913, little was known about the cause of the condition until MRI studies were performed in the 1990s.

Signs and symptoms

Early symptoms of HACE generally correspond with those of moderate to severe acute mountain sickness (AMS). [2] Initial symptoms of HACE commonly include confusion, loss of consciousness, [3] fever, ataxia, [4] photophobia, rapid heart beat, [5] lassitude, and an altered mental state. [2] Those affected generally attempt to cease physical activities, regardless of their necessity for survival. Severe headaches develop and people lose the ability to sit up. [5] Retinal venous dilation occurs in 59% of people with HACE. [6] Rarer symptoms include brisk deep tendon reflexes, retinal hemorrhages, blurred vision, extension plantar reflexes, and ocular paralysis. [5] Cranial nerve palsies occur in some unusual cases. [7]

In the bestselling 1996 non-fiction book Into Thin Air: A Personal Account of the Mt. Everest Disaster, Jon Krakauer describes the effects of HACE upon Dale Kruse, a forty-four-year-old dentist and one of the members of Scott Fischer's team:
'Kruse was having an incredibly difficult time simply trying to dress himself. He put his climbing harness on inside out, threaded it through the fly of his wind suit, and failed to fasten the buckle; fortunately, Fischer and Neal Beidleman noticed the screwup before Kruse started to descend. "If he'd tried to rappel down the ropes like that," says Beidleman, "he would have immediately popped out of his harness and fallen to the bottom of the Lhotse Face." '"It was like I was very drunk," Kruse recollects. "I couldn't walk without stumbling, and completely lost the ability to think or speak. It was a really strange feeling. I'd have some word in my mind, but I couldn't figure out how to bring it to my lips. So Scott and Neal had to get me dressed and make sure my harness was on correctly, then Scott lowered me down the fixed ropes." By the time Kruse arrived in Base Camp, he says, "it was still another three or four days before I could walk from my tent to the mess tent without stumbling all over the place."'

Patients with HACE have an elevated white blood cell count, but otherwise their blood count and biochemistry are normal. If a lumbar puncture is performed, it will show normal cerebral spinal fluid and cell counts but an increase in pressure. [8] In one study, CT scans of patients with HACE exhibited ventricle compression and low density in the cerebellum. [8] Only a few autopsies have been performed on fatal cases of HACE; [9] they showed swollen gyri, spongiosis of white matter, and compressed sulci. There was some variation between individuals, and the results may not be typical of HACE deaths. [9]

Mechanism

Most people who travel to high altitudes acclimatize. Acclimatization precludes the development of HACE by maintaining adequate levels of cerebral oxygen. [10] The primary cause of HACE is hypoxia (oxygen deprivation). [11] This occurs after the body is exposed to a low-oxygen environment and before it acclimatizes. The rate of change from a normal oxygen environment and how little oxygen is in the new environment can be used to predict the chance of developing HACE. [12] Prolonged exertion in low oxygen also causes serious hypocapnia, lower carbon dioxide in the bloodstream, [13] which may play a role in HACE. [14] These factors cause the brain to swell with fluid, resulting in severe impairment. [15] If the swelling is untreated, it causes death by brain herniation. [4]

The brain swelling is likely a result of vasogenic edema, the penetration of the blood–brain barrier by fluids. [16] This process has been observed in MRI studies. Hypoxia increases extracellular fluid, which passes through the vasogenic endothelium in the brain. The leaking may be caused by increased pressure, or it may be caused by inflammation that makes the endothelium vulnerable to leaking. [9] An MRI study found microhemorrhages in the corpus callosum of HACE patients, [16] and hypoxia may also cause microvascular permeability. [9] It has been hypothesized that vascular endothelial growth factor may cause the vascular permeability at the root of HACE. [17] MRI scans of patients with HACE showed increased T2 in the corpus callosum, although grey matter was unchanged. This demonstrated that the blood-brain barrier was broken by cerebral blood vessels, thus interfering with white matter metabolism. [18] Another study looked at the brains of people with HACE several months after their recovery; it showed hemosiderin deposits in the corpus callosum, evidence of vascular permeability. [8]

While there is strong evidence that vasogenic edema plays a major role in HACE, cytotoxic edema, cellular retention of fluids, may contribute as well. [13] [18] Cytotoxic edema may be caused by the failure of cellular ion pumps, which results from hypoxia. Then intracellular sodium and osmolarity increase, and there is an influx of water that causes cellular swelling. [9] [19] After the failure of the ATPase pumps, free radicals form and cause damage that complicates the edema. [13] Evidence against cytotoxic edema includes the high levels of hypoxemia (low bloodstream oxygen) needed to cause it. [20]

It is not known why some are more vulnerable to HACE than others. One theory is that variations in brain size play a role, but the increase in brain volume from edema does not likely cause cranial vault impingement. [17] The presence of large sulci indicate the condition may be influenced by the brain tightly fitting. [21] Elevated intracranial pressure is generally accepted to be a late effect of HACE. [22] [23] High central venous pressure may also occur late in the condition's progression. [17]

One study demonstrated that normal autorelation of cerebral blood flow does not cause HACE. [19] What role the sympathetic nervous system plays in determining who gets HACE is unclear, but it may have an effect. [24]

Another theory about the cause of HACE is that hypoxia may induce nitrous oxide synthase. [25] Vasodilation is caused by the release of nitric oxide and adenosine. [13] This in turn can increase vascular permeability and causes edema. This may combine with low levels of cytokines to cause HACE. [25]

Diagnosis

Generally, high-altitude pulmonary edema (HAPE) or AMS precede HACE. [3] In patients with AMS, the onset of HACE is usually indicated by vomiting, headache that does not respond to non-steroidal anti-inflammatory drugs, hallucinations, and stupor. [16] [20] In some situations, however, AMS progresses to HACE without these symptoms. [16] HACE must be distinguished from conditions with similar symptoms, including stroke, intoxication, psychosis, [2] diabetic symptoms, meningitis, [20] or ingestion of toxic substances. [5] It should be the first diagnosis ruled out when sickness occurs while ascending to a high altitude. [7]

Prevention

HACE is generally preventable by ascending gradually with frequent rest days while climbing or trekking. [26] [20] Not ascending more than 1,000 metres (3,300 ft) daily and not sleeping at a greater height than 300 metres (980 ft) more than the previous night is recommended. [27] The risk of developing HACE is diminished if acetazolamide or dexamethasone are administered. [16] Generally, the use of acetazolamide is preferred, but dexamethasone can be used for prevention if there are side effects or contraindications. [28] Some individuals are more susceptible to HACE than others, [20] and physical fitness is not preventive. [29] Age and sex do not by themselves affect vulnerability to HACE. [5]

Treatment

Patients with HACE should be brought to lower altitudes and provided supplemental oxygen, [18] and rapid descent is sometimes needed to prevent mortality. [30] Early recognition is important because as the condition progresses patients are unable to descend without assistance. [9] Dexamethasone should also be administered, [16] although it fails to ameliorate some symptoms that can be cured by descending to a lower altitude. [9] It can also mask symptoms, and they sometimes resume upon discontinuation. [20] Dexamethasone's prevention of angiogenesis may explain why it treats HACE well. [17] Three studies that examined how mice and rat brains react to hypoxia gave some credence to this idea. [17] [25]

If available, supplemental oxygen can be used as an adjunctive therapy, or when descent is not possible. FiO2 should be titrated to maintain arterial oxygen saturation of greater than 90%, bearing in mind that oxygen supply is often limited in high altitude clinics/environments. [31]

In addition to oxygen therapy, a portable hyperbaric chamber (Gamow bag) can by used as a temporary measure in the treatment of HACE. These devices simulate a decrease in altitude of up to 7000 ft, but they are resource intensive and symptoms will often return after discontinuation of the device. Portable hyperbaric chambers should not be used in place of descent or evacuation to definitive care. [32]

Diuretics may be helpful, but pose risks outside of a hospital environment. [9] Sildenafil and tadalafil may help HACE, [33] but there is little evidence of their efficacy. [34] Theophylline is also theorized to help the condition. [34]

Although AMS is not life-threatening, [20] HACE is usually fatal within 24 hours if untreated. [4] Without treatment, the patient will enter a coma [4] and then die. [4] In some cases, patients have died within a few hours, and a few have survived for two days. [5] Descriptions of fatal cases often involve climbers who continue ascending while experiencing the condition's symptoms. [5]

Prognosis

Recovery varies between days and weeks, [9] but most recover in a few days. [26] After the condition is successfully treated, it is possible for climbers to reascend. Dexamethesone should be discontinued, but continual acetazolamide is recommended. [30] In one study, it took patients between one week and one month to display a normal CT scan following HACE. [8]

Epidemiology

HACE occurs in 0.5% to 1% of people who climb or trek between 4,000 metres (13,000 ft) and 5,000 metres (16,000 ft). [16] In some unusual cases, up to 30% of members of expeditions have had the condition. [5] The condition is seldom seen below 3,000 metres (9,800 ft), [5] but in some rare cases it has developed as low as 2,500 metres (8,200 ft). [35] The condition generally does not occur until an individual has spent 48 hours at an altitude of 4,000 metres (13,000 ft). [16]

History

HACE was first described by a medical officer stationed in Chile in 1913, but few took note of it. [5] [27] Later, access to air travel made the condition more common because it allowed more people access to high mountains, such as those in the Himalayas. [3] One early description of HACE may have been published in 1969 after a group of Indian soldiers made a rapid ascent to almost 6,000 metres (20,000 ft). [36] It is not definitely established whether they had HACE or acute decompression sickness. [22] MRI has been used to study the effects of high altitude on the brain, [18] providing the best evidence about the condition. [20] A 1998 MRI study of nine climbers with HACE clearly demonstrated vasogenic edema. [37]

Data about HACE are lacking because it generally occurs in remote areas, far from hospitals [38] and is generally rare. [29] It is uncommon for doctors to be able to study victims within six days of the condition's development. [19] Animal models of HACE have not been developed. [39] Several genes are being examined for the role they may play in the development of the condition. [40]

Increased education and helicopter capabilities have combined to cut the number of deaths from the condition. [8] Symptoms of HACE have been reported in many cases of deaths while descending Mount Everest, although HACE may not be the only problem they experienced. [7] HACE also posed a threat to workers on the Qinghai–Tibet Railway. [27]

Related Research Articles

<span class="mw-page-title-main">Hypoxia (medical)</span> Medical condition of lack of oxygen in the tissues

Hypoxia is a condition in which the body or a region of the body is deprived of adequate oxygen supply at the tissue level. Hypoxia may be classified as either generalized, affecting the whole body, or local, affecting a region of the body. Although hypoxia is often a pathological condition, variations in arterial oxygen concentrations can be part of the normal physiology, for example, during strenuous physical exercise.

<span class="mw-page-title-main">Altitude sickness</span> Medical condition due to rapid exposure to low oxygen at high altitude

Altitude sickness, the mildest form being acute mountain sickness (AMS), is the harmful effect of high altitude, caused by rapid exposure to low amounts of oxygen at high elevation. People can respond to high altitude in different ways. Symptoms may include headaches, vomiting, tiredness, confusion, trouble sleeping, and dizziness. Acute mountain sickness can progress to high-altitude pulmonary edema (HAPE) with associated shortness of breath or high-altitude cerebral edema (HACE) with associated confusion. Chronic mountain sickness may occur after long-term exposure to high altitude.

<span class="mw-page-title-main">Papilledema</span> Eye disorder

Papilledema or papilloedema is optic disc swelling that is caused by increased intracranial pressure due to any cause. The swelling is usually bilateral and can occur over a period of hours to weeks. Unilateral presentation is extremely rare.

<span class="mw-page-title-main">Dexamethasone</span> Corticosteroid medication

Dexamethasone is a glucocorticoid medication used to treat rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye pain following eye surgery, superior vena cava syndrome, and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it may be used in combination with a mineralocorticoid medication such as fludrocortisone. In preterm labor, it may be used to improve outcomes in the baby. It may be given by mouth, as an injection into a muscle, as an injection into a vein, as a topical cream or ointment for the skin or as a topical ophthalmic solution to the eye. The effects of dexamethasone are frequently seen within a day and last for about three days.

<span class="mw-page-title-main">Acetazolamide</span> Chemical compound

Acetazolamide, sold under the trade name Diamox among others, is a medication used to treat glaucoma, epilepsy, altitude sickness, periodic paralysis, idiopathic intracranial hypertension, heart failure and to alkalinize urine. It may be used long term for the treatment of open angle glaucoma and short term for acute angle closure glaucoma until surgery can be carried out. It is taken by mouth or injection into a vein. Acetazolamide is a first generation carbonic anhydrase inhibitor and it decreases the ocular fluid and osmolality in the eye to decrease intraocular pressure.

<span class="mw-page-title-main">Cerebral edema</span> Excess accumulation of fluid (edema) in the intracellular or extracellular spaces of the brain

Cerebral edema is excess accumulation of fluid (edema) in the intracellular or extracellular spaces of the brain. This typically causes impaired nerve function, increased pressure within the skull, and can eventually lead to direct compression of brain tissue and blood vessels. Symptoms vary based on the location and extent of edema and generally include headaches, nausea, vomiting, seizures, drowsiness, visual disturbances, dizziness, and in severe cases, coma and death.

<span class="mw-page-title-main">Pulmonary edema</span> Fluid accumulation in the tissue and air spaces of the lungs

Pulmonary edema, also known as pulmonary congestion, is excessive liquid accumulation in the tissue and air spaces of the lungs. It leads to impaired gas exchange and may cause hypoxemia and respiratory failure. It is due to either failure of the left ventricle of the heart to remove oxygenated blood adequately from the pulmonary circulation, or an injury to the lung tissue directly or blood vessels of the lung.

<span class="mw-page-title-main">Polycythemia</span> Laboratory diagnosis of high hemoglobin content in blood

Polycythemia is a laboratory finding in which the hematocrit and/or hemoglobin concentration are increased in the blood. Polycythemia is sometimes called erythrocytosis, and there is significant overlap in the two findings, but the terms are not the same: polycythemia describes any increase in hematocrit and/or hemoglobin, while erythrocytosis describes an increase specifically in the number of red blood cells in the blood.

<span class="mw-page-title-main">Death zone</span> Mountaineering term

In mountaineering, the death zone refers to altitudes above a certain point where the pressure of oxygen is insufficient to sustain human life for an extended time span. This point is generally tagged as 8,000 m. The concept was conceived in 1953 by Edouard Wyss-Dunant, a Swiss doctor, who called it the lethal zone. All 14 peaks above 8000 m in the death zone are located in the Himalaya and Karakoram of Asia.

<span class="mw-page-title-main">Generalized hypoxia</span> Medical condition of oxygen deprivation

Generalized hypoxia is a medical condition in which the tissues of the body are deprived of the necessary levels of oxygen due to an insufficient supply of oxygen, which may be due to the composition or pressure of the breathing gas, decreased lung ventilation, or respiratory disease, any of which may cause a lower than normal oxygen content in the arterial blood, and consequently a reduced supply of oxygen to all tissues perfused by the arterial blood. This usage is in contradistinction to localized hypoxia, in which only an associated group of tissues, usually with a common blood supply, are affected, usually due to an insufficient or reduced blood supply to those tissues. Generalized hypoxia is also used as a synonym for hypoxic hypoxia This is not to be confused with hypoxemia, which refers to low levels of oxygen in the blood, although the two conditions often occur simultaneously, since a decrease in blood oxygen typically corresponds to a decrease in oxygen in the surrounding tissue. However, hypoxia may be present without hypoxemia, and vice versa, as in the case of infarction. Several other classes of medical hypoxia exist.

<span class="mw-page-title-main">High-altitude pulmonary edema</span> Human disease

High-altitude pulmonary edema (HAPE) is a life-threatening form of non-cardiogenic pulmonary edema that occurs in otherwise healthy people at altitudes typically above 2,500 meters (8,200 ft). However, cases have also been reported between 1,500–2,500 metres or 4,900–8,200 feet in more vulnerable subjects.

Stridor is a high-pitched extra-thoracic breath sound resulting from turbulent air flow in the larynx or lower in the bronchial tree. It is different from a stertor which is a noise originating in the pharynx. Stridor is a physical sign which is caused by a narrowed or obstructed airway. It can be inspiratory, expiratory or biphasic, although it is usually heard during inspiration. Inspiratory stridor often occurs in children with croup. It may be indicative of serious airway obstruction from severe conditions such as epiglottitis, a foreign body lodged in the airway, or a laryngeal tumor. Stridor should always command attention to establish its cause. Visualization of the airway by medical experts equipped to control the airway may be needed.

<span class="mw-page-title-main">Cerebral hypoxia</span> Oxygen shortage of the brain

Cerebral hypoxia is a form of hypoxia, specifically involving the brain; when the brain is completely deprived of oxygen, it is called cerebral anoxia. There are four categories of cerebral hypoxia; they are, in order of increasing severity: diffuse cerebral hypoxia (DCH), focal cerebral ischemia, cerebral infarction, and global cerebral ischemia. Prolonged hypoxia induces neuronal cell death via apoptosis, resulting in a hypoxic brain injury.

Hypoxic pulmonary vasoconstriction (HPV), also known as the Euler-Liljestrand mechanism, is a physiological phenomenon in which small pulmonary arteries constrict in the presence of alveolar hypoxia. By redirecting blood flow from poorly-ventilated lung regions to well-ventilated lung regions, HPV is thought to be the primary mechanism underlying ventilation/perfusion matching.

Chronic mountain sickness (CMS) is a disease in which the proportion of blood volume that is occupied by red blood cells increases (polycythaemia) and there is an abnormally low level of oxygen in the blood (hypoxemia). CMS typically develops after extended time living at high altitude. It is most common amongst native populations of high altitude nations. The most frequent symptoms of CMS are headache, dizziness, tinnitus, breathlessness, palpitations, sleep disturbance, fatigue, loss of appetite, confusion, cyanosis, and dilation of veins.

<span class="mw-page-title-main">Carbonic anhydrase inhibitor</span> Class of pharmaceuticals

Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase. Their clinical use has been established as anti-glaucoma agents, diuretics, antiepileptics, in the management of mountain sickness, gastric and duodenal ulcers, idiopathic intracranial hypertension, neurological disorders, or osteoporosis.

<span class="mw-page-title-main">Posterior reversible encephalopathy syndrome</span> Medical condition

Posterior reversible encephalopathy syndrome (PRES), also known as reversible posterior leukoencephalopathy syndrome (RPLS), is a rare condition in which parts of the brain are affected by swelling, usually as a result of an underlying cause. Someone with PRES may experience headache, changes in vision, and seizures, with some developing other neurological symptoms such as confusion or weakness of one or more limbs. The name of the condition includes the word "posterior" because it predominantly though not exclusively affects the back of the brain. Common underlying causes are severely elevated blood pressure, kidney failure, severe infections, certain medications, some autoimmune diseases, and pre-eclampsia. The diagnosis is usually made by brain scan (MRI) on which areas of swelling can be identified.

<span class="mw-page-title-main">Effects of high altitude on humans</span> Environmental effects on physiology

The effects of high altitude on humans are mostly the consequences of reduced partial pressure of oxygen in the atmosphere. The oxygen saturation of hemoglobin determines the content of oxygen in blood. After the human body reaches around 2,100 metres (6,900 ft) above sea level, the saturation of oxyhemoglobin begins to decrease rapidly. However, the human body has both short-term and long-term adaptations to altitude that allow it to partially compensate for the lack of oxygen. There is a limit to the level of adaptation; mountaineers refer to the altitudes above 8,000 metres (26,000 ft) as the death zone, where it is generally believed that no human body can acclimatize. At extreme altitudes, the ambient pressure can drop below the vapor pressure of water at body temperature, but at such altitudes even pure oxygen at ambient pressure cannot support human life, and a pressure suit is necessary. A rapid depressurisation to the low pressures of high altitudes can trigger altitude decompression sickness.

Grinker's myelinopathy, also known as anoxic leukoencephalopathy, is a rare disease of the central nervous system. The disease is characterized by a delayed leukoencephalopathy after a hypoxic episode. It is typically, though not necessarily, related to carbon monoxide poisoning or heroin overdose. It occurs in roughly 2.8% of those who experience an acute hypoxic/anoxic episode. Because of the wide range of symptoms and the delay in onset, it is often misdiagnosed as other neuropathologies. Grinker's myelinopathy was originally characterized by Roy R. Grinker in 1925 or 1926, depending on the source.

<span class="mw-page-title-main">Silent hypoxia</span> Type of presentation of generalised hypoxia

Silent hypoxia is generalised hypoxia that does not coincide with shortness of breath. This presentation is known to be a complication of COVID-19, and is also known in walking pneumonia, altitude sickness, and rebreather diving.

References

  1. ↑ 'Oedema' is the standard form defined in the Concise Oxford English Dictionary (2011), with the precision that the spelling in the United States is 'edema'.
  2. 1 2 3 Bärtsch & Swenson 2013, p. 2296.
  3. 1 2 3 Rosenberg 2012, p. 146.
  4. 1 2 3 4 5 Bärtsch & Swenson 2013, p. 2294.
  5. 1 2 3 4 5 6 7 8 9 10 Schoene et al. 2012, p. 301.
  6. ↑ Wilson, Newman & Imray 2009, p. 185.
  7. 1 2 3 Wilson, Newman & Imray 2009, p. 177.
  8. 1 2 3 4 5 Schoene et al. 2012, p. 303.
  9. 1 2 3 4 5 6 7 8 9 Schoene et al. 2012, p. 304.
  10. ↑ Imray et al. 2010, p. 470.
  11. ↑ Imray et al. 2010, p. 468.
  12. ↑ Imray et al. 2010, p. 469.
  13. 1 2 3 4 Rosenberg 2012, p. 147.
  14. ↑ Wilson, Newman & Imray 2009, p. 182.
  15. ↑ Rosenberg 2012, pp. 146–50.
  16. 1 2 3 4 5 6 7 8 Bärtsch & Swenson 2013, p. 2295.
  17. 1 2 3 4 5 Schoene et al. 2012, p. 306.
  18. 1 2 3 4 Rosenberg 2012, p. 148.
  19. 1 2 3 Schoene et al. 2012, p. 305.
  20. 1 2 3 4 5 6 7 8 Schoene 2008.
  21. ↑ Wilson, Newman & Imray 2009, p. 183.
  22. 1 2 Wilson, Newman & Imray 2009, p. 181.
  23. ↑ Imray et al. 2010, p. 474.
  24. ↑ Imray et al. 2010, p. 472.
  25. 1 2 3 Schoene et al. 2012, p. 307.
  26. 1 2 Imray et al. 2010, p. 467.
  27. 1 2 3 Wilson, Newman & Imray 2009, p. 175.
  28. ↑ Bärtsch & Swenson 2013, p. 2298.
  29. 1 2 Imray et al. 2010, p. 471.
  30. 1 2 Bärtsch & Swenson 2013, p. 2299.
  31. ↑ Luks, Andrew; Scott E. Macintosh; Colin K. Grissom; Paul S Auerbach; George W Rodway; Robert B Schoene; Ken Zafren; Peter H Hackett (June 2010). "Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness". Wilderness & Environmental Medicine. 21 (2): 146–155. doi: 10.1016/j.wem.2010.03.002 . PMID   20591379 . Retrieved 13 December 2013.
  32. ↑ Luks, Andrew; Scott E. Macintosh; Colin K. Grissom; Paul S Auerbach; George W Rodway; Robert B Schoene; Ken Zafren; Peter H Hackett (June 2010). "Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness". Wilderness & Environmental Medicine. 21 (2): 146–155. doi: 10.1016/j.wem.2010.03.002 . PMID   20591379 . Retrieved 13 December 2013.
  33. ↑ Wilson, Newman & Imray 2009, p. 179.
  34. 1 2 Imray et al. 2010, p. 478.
  35. ↑ Wilson, Newman & Imray 2009, p. 176.
  36. ↑ Rosenberg 2012, pp. 146 & 150.
  37. ↑ Wilson, Newman & Imray 2009, p. 184.
  38. ↑ Bärtsch & Swenson 2013, p. 2300.
  39. ↑ Imray et al. 2010, p. 475.
  40. ↑ Wilson, Newman & Imray 2009, p. 180.

Bibliography

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.